13 January 2020
Your comments on the proposed adoption or non-adoption of these EU guidelines, particularly your advice on whether you support the proposed action, would be appreciated.
Comments may be sent by email or mail and should include your full contact details.
The email address for comments is: email@example.com
The postal address for comments is:
EU/ICH Guidelines Coordinator
Office of Medicines Authorisation
Therapeutic Goods Administration
PO Box 100
WODEN ACT 2606
Guidelines proposed for adoption – click here to view.
Closing date: 7 February 2020